The influence of the charge and of the tin-ligand ratio on bone uptake of technetium 99m labelled osteotropic radiopharmaceuticals.
This work describes the determination of the charge for various 99mTc-Sn-phosphonate complexes. The variation of the Sn/P ratio using an HMDP ligand produces complexes with different negative charges. Biological distribution studies show superior bone uptake of strongly negative charged complexes.
D000818:Animals; D001842:Bone and Bones / Q000378:metabolism*; D055598:Chemical Phenomena; D002621:Chemistry; D004164:Diphosphonates / Q000378:metabolism*; D004563:Electrochemistry; D007700:Kinetics; D008099:Liver / Q000378:metabolism; D008297:Male; D009942:Organometallic Compounds / Q000378:metabolism*; D015609:Organotechnetium Compounds; D051381:Rats; D011919:Rats, Inbred Strains; D013329:Structure-Activity Relationship; D013667:Technetium; D013669:Technetium Tc 99m Medronate / Q000031:analogs & derivatives* / Q000378:metabolism*; D014001:Tin
D004164:Diphosphonates; D009942:Organometallic Compounds; D015609:Organotechnetium Compounds; C052435:technetium Tc 99m (Sn) hydroxymethylene diphosphonate; C052434:technetium Tc 99m (Sn)-imidodiphosphonic acid; C023568:technetium Tc 99m (Sn)methylenediphosphonate; D013667:Technetium; D014001:Tin; D013669:Technetium Tc 99m Medronate